UTIs in men are uncommon, and a week of antibiotics works as well as two

Urinary tract infections are far less common in men than in women, and for a man who is not systemically ill the modern evidence points two ways at once: treat a genuine, symptomatic infection, but do not treat bacteria found in urine that is causing no symptoms [s2][s3]. When treatment is warranted, a randomised trial found that seven days of antibiotics resolved symptoms as well as the traditional fourteen [s1].

A different infection, recently reclassified

For decades a UTI in a man was treated as inherently "complicated," on the reasoning that male urinary infections are unusual and often signal an underlying problem. That framing is shifting. A 2026 systematic review notes that updated Infectious Diseases Society of America guidelines have reclassified UTI in men without signs of systemic infection — with or without anatomical abnormalities — from complicated to uncomplicated infection, which changes how it is diagnosed and managed [s2].

The same review is a useful reminder of how thin the hard epidemiology still is. Searching two decades of the literature, its authors found only five studies with usable incidence or prevalence data, from Japan, the Netherlands, Turkey, Uganda and the United States, with sample sizes from 18 to 4,876 and median ages of 44 to 71 years [s2]. In the Dutch dataset, the incidence of uncomplicated UTI in men was 6.5 per 1,000 person-years and rose with age [s2]. Escherichia coli was the culprit organism in between 32.9% and 94% of cases across the studies — the same bug that dominates female UTIs, but with far more variable resistance patterns [s2].

The treatment-length question

The strongest evidence on how long to treat comes from a 2021 trial in afebrile men — those without fever, the group in whom a shorter course is most plausible. Investigators at two US Veterans Affairs medical centres enrolled men with symptomatic UTI who had already been prescribed ciprofloxacin or trimethoprim-sulfamethoxazole, and randomised 272 of them to stop active antibiotics at seven days, switching to placebo, or to continue to fourteen days [s1].

Symptoms resolved in 122 of 131 men (93.1%) in the seven-day group versus 111 of 123 (90.2%) on fourteen days, a difference of 2.9% that met the trial's pre-specified non-inferiority margin of 10% [s1]. Symptom recurrence within 28 days ran at 9.9% on the short course against 12.9% on the long one, and adverse events at 20.6% versus 24.3% — both numerically lower with fewer days of antibiotic, though the trial was not designed to prove the shorter course actively safer [s1]. These were older men, with a median age of 69 [s1]. The result matters because every extra day of antibiotic adds cost, side effects and selective pressure for resistance without, here, buying better cure rates.

The other half of the evidence: restraint

The counterpart to "treat symptomatic infection briefly" is "do not treat colonisation at all." The IDSA's 2019 guideline recommends against screening for, or treating, asymptomatic bacteriuria — bacteria present in the urine with no accompanying symptoms — in older men, among other groups [s3]. The guideline is explicit that antimicrobial treatment of asymptomatic bacteriuria has come to be recognised as an important contributor to inappropriate antibiotic use [s3]. A positive urine culture in a man with no urinary symptoms is, on this evidence, usually a reason to do nothing rather than to prescribe.

That distinction is the practical crux, because a cloudy or strong-smelling specimen, or a colonised catheter, invites over-treatment. The honest reading of the guideline is that the test result alone does not diagnose an infection; symptoms do [s3].

What it means for a reader

The shape of the evidence is narrower and more consistent than the old "male UTIs are always complicated" rule suggested. A man with genuine urinary symptoms is treated, increasingly for about a week rather than two [s1]; a man whose urine merely grows bacteria without symptoms generally is not [s3]. The harder clinical work lies in telling a true bladder infection apart from prostate inflammation (see chronic prostatitis and pelvic pain) or from the incomplete emptying caused by an enlarged prostate, both of which can mimic or predispose to infection.

Prevention strategies that have been studied mainly in women — cranberry products and the urinary antiseptic methenamine — carry their own mixed and, for men, largely untested evidence, and none is a reason to treat a symptomless culture. As health systems lean on algorithms to flag urinary infections, the same principle holds: the decision to prescribe should turn on symptoms and the shortest effective course, not on the bare fact that bacteria are present.